

1 *Type of the Paper (Article)*

2 **Antibiofilm activity of dual-function Tail tubular** 3 **protein B from KP32 phage on *Enterobacter cloacae***

4 Ewa Brzozowska ^{1*}, Anna Pyra ^{2**}, Krzysztof Pawlik ¹ and Andrzej Gamian ¹

5 ¹ L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy
6 of Sciences, 12 R. Weigl, 53-114 Wrocław, Poland; ezuziak@iitd.pan.wroc.pl, pawlik@iitd.pan.wroc.pl,
7 gamian@iitd.pan.wroc.pl

8 ² Faculty of Chemistry, Department of Crystallography, University of Wrocław, 14 F. Joliot-Curie, 50-383
9 Wrocław, Poland, anna.pyra@chem.uni.wroc.pl

10 * Correspondence: ezuziak@iitd.pan.wroc.pl, ** anna.pyra@chem.uni.wroc.pl

12 **Abstract:**

13 Background: Dual function tail tubular proteins (TTP) from lytic bacteriophage are novel
14 interesting group of biologically active enzymes possessing antibiofilm activity. Surprisingly, apart
15 from their structural function, they are also polysaccharide hydrolyzes destroying bacterial
16 extracellular components. One of the representatives of this group is TTPB from KP32 phage. Here,
17 we present its biological activity towards biofilm of *E. cloacae* ATCC 13047 strain and towards its
18 exopolysaccharide (EPS).

19 Methods: TTPB was overexpressed in *E. coli* system, purified and tested towards the pathogenic
20 bacteria using agar overlay method. Hydrolytic activity of TTPB against bacterial EPS has been
21 performed by reducing sugar (RS) determination in TTPB/EPS mixture regarding the RS amount
22 obtained after acidic hydrolysis. Antibiofilm activity of TTPB has been set down on one-day *E.*
23 *cloacae* biofilm using a biochemical method. Finally, the synergistic activity of TTPB with
24 kanamycin has been demonstrated.

25 Results: For the first time the hydrolytic activity of TTPB towards bacterial EPS has been showed.
26 TTPB releases about a half of the whole RS amount of *E. cloacae* ATCC 13047 EPS and can reduce
27 its biofilm by over 60%. Destroying the bacterial biofilm the phage protein improves the antibiotic
28 action increasing kanamycin effectiveness almost four times.

29 **Keywords:** tail tubular protein B, bacteriophage, biofilm, exopolysaccharide, hydrolytic activity

30 **Introduction**

31 Nowadays, drug-resistance of pathogenic bacteria is a serious problem. High degree of the
32 antibiotic- resistance is related to biofilm production ability and bacteria survival in hospital
33 environment. Biofilm is an organized structure, in which bacterial cells stick to each other on a
34 various solid surfaces forming large aggregates. They are often enclosed by thick polysaccharide
35 layer which makes them resistant to antibiotics and thus very hard to eliminate [1]. The major
36 biofilm adhesion factors - bacterial polysaccharide - is secreted outside the cell, and hence called
37 exopolysaccharide (EPS) [2]. EPS forms a shell (capsular EPS) or is secreted outside the cell as
38 mucus (slime EPS) [3]. EPS assists in settling in the environment and forms a protective barrier
39 against adverse environmental conditions and biological factors. EPS being a major component
40 of the biofilm impedes antibiotic penetration to the interior of the biofilm [4]. On the other hand,
41 the biofilm associated antibiotic resistance may be reduced by polysaccharide depolymerases
42 (PD) use. A promising alternative in this field seem to be bacteriophage derived PD application
43 [5]. Based on the latest search, phage PD are very diverse in their molecular mass, structure and

44 mechanism of action and the huge majority of them are encoded in the same open reading frame
45 of phage structural proteins, and were thus considered as structural proteins [6-8]. The huge
46 diversity of phage PD is resulted from the co-evolution of phages and their host bacteria [9]. One
47 of the most refractory pathogen causing biofilm associated infections is *Enterobacter cloacae*. *E.*
48 *cloacae* is a Gram positive bacteria causing a range of nosocomial infections in human, urinary
49 tract infections, biliary tract infections osteomyelitis, cholecystitis, and neonatal meningitis [10].
50 [4]. Here, we present a novel dual-function phage protein named tail tubular protein B (TTPB)
51 from KP32 phage possessing antibiofilm activity on *E. cloacae* bacteria. TTPB inhibits biofilm
52 formation by *E. cloacae* ATCC 13047 strain and hydrolyses its EPS. This phage protein facilitates
53 antibiotic to break through the biofilm barrier and cooperates with the antibiotic in bacterial
54 biofilm destruction.

55 **Materials and Methods**

56 Bacterial strain of *E. cloacae* ATCC 13047 was obtained from the Polish Collection of
57 Microorganisms (PCM) of the Institute of Immunology and Experimental Therapy, Polish Academy
58 of Sciences (Wroclaw, Poland), the PCM number of 533. The strain was stored at -80°C and
59 cultivated in Luria-Bertani (LB) broth medium (Difco). Bacteria were cultured at 37°C stationary or
60 with shaking.

61 Cloning procedure

62 Gene g32 of KP32 phage was obtained using polymerase chain reaction (PCR) with the following
63 primers: GP32FW – GGATCCCATATGGCTCTCGTATCACAATCA, GP32RV –
64 GAATTCAAAGCTTAATACCGTTAGCGGTCT. The KP32 DNA template was obtained from the
65 Institute of Genetics and Microbiology, University of Wroclaw, Poland. PCR reactions were
66 conducted using a two-phase standard program. The first phase consisted of seven and the second
67 phase of 23 cycles. Taq polymerase (Fermentas) was used and the annealing time was max. 2
68 minutes. Annealing temperature in the first phase was 48°C-52°C and in the second phase 55°C-
69 65°C. PCR product was cloned into pGEM T-easy vector (T-vector, Promega) using T4 ligase. T-
70 vector was transformed into *E. coli* DH5 α bacteria using the heat-shock method. The correctness of
71 cloning was analyzed using the white/blue colony selection system. Selected clones were inoculated
72 and their plasmid DNA was isolated using a mini-prep kit (Promega) and digested using EcoRI
73 restriction enzyme. The DNA fragments were electrophoretically analyzed and cut out from the
74 agar gel and then sequenced (Genomed) using T7 and SP6 primers. Correct sequences were cloned
75 into pET28a (Promega) expression vectors containing a gene for conferring kanamycin resistance.
76 The vectors express KP phage tail protein with an N-terminal six-histidine tag. Plasmid
77 transformation into competent *E. coli* BL21(DE3)plysS (Promega) cells was done using the heat
78 shock method and then inoculated on LB agar with the antibiotics kanamycin and chloramphenicol.

79 TTPB expression and purification

80 TTPB was expressed in *E. coli* BL21 (DE3)plysS strain (Promega). Bacterial clones were propagated
81 in LB broth (37°C with shaking) with kanamycin and chloramphenicol to reach OD₆₀₀ = 0.8.
82 Induction of gene expression was performed using 0.05 mM IPTG (Roche) and following overnight
83 incubation at 9°C cells were pelleted and suspended in 50 mM Tris/HCl pH = 8.0 lysis buffer
84 containing 1 M NaCl and 10% glycerol supplemented with protease inhibitor cocktail tablets
85 (Roche). Cells were sonicated 8 times for 30 seconds with breaks lasting 1 minute. After debris
86 removal via centrifugation (14000g for 50 minutes) supernatant was mixed with Ni²⁺
87 chromatography gel and incubated for 1 hour at 37°C on a rotary shaker. After batch
88 chromatography the unbound fraction was removed on a Buchner funnel. Proteins bound to Ni
89 ions were eluted using lysis buffer containing 250 mM imidazole. Imidazole was removed via
90 dialysis on centrifugal filters containing membrane (Millipore) with a cut-off of 30 kDa.

91 Concentration of proteins was determined using the BCA method by Smith et al. (11) and analyzed
92 in SDS-PAGE electrophoresis using 12.5% gels according to the method of Laemmli et al.[12].

93 Hydrolytic activity

94 EPS of *E. cloacae* ATCC 13047 was extracted using 3 volumes of 96% ethanol (4°C, overnight) from
95 supernatant obtained after centrifugation of one-day bacterial culture. The pelleted slime was
96 obtained after centrifugation (14000g for 30 minutes at 4°C) then dissolved in water, dialyzed
97 against water, frozen and lyophilized. The reaction mixture contained 100 µg of EPS and 100 µl of
98 0.56 µM of TTPB and was incubated for 2 h at 37°C on a rotary shaker. Enzyme activity was
99 determined using reducing sugars (RS) determination with glucose as a standard according to
100 Nelson-Somogoi method [13]. The RS amount was compared to the total amount of RS released
101 after EPS (100 µg of dry mass) acid hydrolysis (10 mol l-1 HCl, 85°C, 25'). The negative control
102 contained EPS (100 µg) and buffer lacking the phage proteins. The acid hydrolysis was performed
103 according to the method of Kubler-Kielb et al. (2004) [14].

104 Agar overlay method

105 Bacteria were cultured overnight in 5 ml of LB broth at 37°C with shaking. Samples of 1 ml of
106 bacteria were inoculated on agar plates and dried. 10 µl (0.025 -0.1 nM) of TTPB and was dotted on
107 a plate and incubated at 37°C overnight.

108 Antibiofilm activity

109 One-day biofilm preparation: Bacteria were cultured overnight in 5 ml of LB broth at 37°C with
110 shaking. Overnight cultures were diluted to OD600 = 0.2 using fresh LB. 100 µl of bacteria
111 suspension was inoculated into a 96-well plate (CytoOne) and incubated for 20 hours at 37°C. After
112 that time bacteria were removed and the plate was dried for 15 minutes up-side-down on a sterile
113 paper towel. TTPB was added (0.56 µM) and incubated at 37°C for the next 24 hours. The next day,
114 the OD600 was measured and after that 50 µl of 0.1% trimethyl tetrazolium chloride (TTC) was
115 added to each well. After 1 hour of incubation at 37°C the OD540 was measured on a Biotec
116 microplate reader. Microtitre plate wells containing growth medium without any bacterial culture –
117 sterility control; wells containing cell cultures but without TTPB – control regarded as 100% cell
118 mass. All trials were performed in triplicate and the mean value was calculated with the standard
119 deviation range.

120 Synergistic action of TTPB with kanamycin on biofilm destruction


121 Bacteria were cultured overnight in 5 ml of LB broth at 37°C with shaking. Overnight cultures were
122 diluted to OD600 = 0.2 using fresh LB. 100 µl of bacteria suspension, 100 µl of protein solutions (0.56
123 µM) and 100 µl of kanamycin (50 µg per well) were inoculated into each well of a 96-well plate and
124 incubated at 37°C for 24 hours. The next day, the bacteria/protein/antibiotic mix was removed and
125 washed 3 times with sterile Milli Q water. Again, 100 µl of bacteria suspension and 100 µl of protein
126 solutions with kanamycin were added into the plate and incubated at 37°C overnight. The above
127 procedure was repeated for 3 days. On the fourth day after washing planktonic bacteria, 125 µl of
128 0.1% crystal violet solution was added and stained for 10 minutes at room temperature. The dye
129 was decanted and the wells were washed with water and allowed to dry. Then 200 µl of 95%
130 ethanol was added and after incubation for 15 minutes, the measurement was performed at 570 nm

131

132 **Results**

133 Cloning, gene expression and protein analysis

134 TTPB was mostly expressed as inclusion bodies, however, the use of elevated concentrations of
135 NaCl and glycerol in the lysis buffer allowed us to obtain almost 100% of soluble protein. TTPB was
136 purified using Ni²⁺ affinity chromatography and eluted by 250 mM imidazole in Tris/HCl buffer
137 containing 1 M NaCl and 10% glycerol. From one liter of bacterial culture 25 milligrams of the pure
138 protein was obtained. After dialysis TTPB was analyzed in SDS-PAGE (Fig. 1) and the established
139 molecular mass was 89 kDa.




140

141 **Figure 1.** Electrophoretic analysis of TTPB after expression and purification. TTPB was analyzed in
142 12.5% SDS-PAGE; A) Low molecular mass standard, B) TTPB after purification on Ni²⁺ affinity
143 chromatography.

144 Agar overlay and antibiofilm test

145 Purified TTPB was tested towards *E. cloacae* ATCC 13047 strain to determine the range of lytic
146 activity. The agar overlay test showed that the phage protein causes plaques on the bacterial lawn
147 (Fig. 2A). The activity zones were translucent not clear plaques suggesting that the enzymatic
148 activity was directed towards bacterial EPS leaving the bacterial cells intake. Further analysis
149 showed that TTPB can reduce bacterial biomasses of above strain. 0.56 μM of TTPB can reduce
150 about 65% of *E. cloacae* strains' biomass after one-day biofilm formation assay. The antibiofilm
151 activity of TTPB is shown in Figure 2B.

152



153


154 **Figure 2.** Antimicrobial activity of TTPB in overlay method towards *E. cloacae* ATCC 13047 (A) and
155 towards the bacterial biofilm (B).

156 Hydrolytic activity

157 100 μg of EPS of *E. cloacae* ATCC 13047 strain contained $0.71 \mu\text{M ml}^{-1}$ of total RS. This total amount
158 of RS was established after EPS acidic hydrolysis. The RS calculation was made using Nelson-
159 Somogoi assay. The EPS hydrolyzed by TTPB gave $0.32 \mu\text{M ml}^{-1}$ of RS and represents a significant
160 proportion (45%) of the total RS of the EPS. The calculation of the RS release has been performed
161 considering the RS present in the control sample lacking TTPB (negative control).

162 Synergistic activity

163 Further analysis showed that TTPB exhibits synergistic antimicrobial activity with kanamycin (Fig.
164 3). Kanamycin was first tested on *E. cloacae* ATCC 13047 lawn to make sure it kills the bacteria.
165 Next, the 4-day old biofilm was cultured on 96-well plates according to the method described in
166 Material and Methods section. It was shown that, the presence of TTPB increased antibiotic activity
167 by almost four times. Kanamycin ($10 \mu\text{g}$ per well) alone inhibited biofilm formation by about 70%
168 and with phage proteins the inhibition percent increased to 84% with respect to control – bacterial
169 biomass obtained in culture without any additives including TTPB. It was interesting result
170 showing the additive effect of antibiotic and the phage protein.



171

172 **Figure 3.** Synergistic activity of TTPB with kanamycin towards *E. cloacae* ATCC 13047 biofilm

173 Primary structure analysis

174 Our analysis of amino acid sequence showed that in term of primary structure TTPB from
 175 bacteriophage KP32 displays a very high identity (61%) with TTPB from T7 bacteriophage. It
 176 suggests these two proteins should display a very similar functional and structural properties.
 177 TTPB from T7 bacteriophage was not considered as a hydrolytic enzyme. We can only suggest that
 178 function. So we can not compare and point any enzymatic active sites of these two tail B proteins.

179 **4. Discussion**

180 Most infections caused by bacterial strains which are capable of biofilm formation are difficult to
 181 treat because of their increased resistance to antibiotics. This resistance of biofilmed bacteria is
 182 attributed to a barrier function of the biofilm which binds the antimicrobial agents within a matrix
 183 and also the metabolic change in the biofilmed bacteria cells [15]. It is suggested that microbial cells
 184 forming a biofilm are even 1000-fold more resistant to antimicrobial agents than their planktonic
 185 counterparts [16]. Bacteriophages seem to be attractive and very effective antibiofilm agents,
 186 because of their capacity for exopolysaccharide matrix degradation, bacterial cell infection and
 187 biofilm structure disruption [17]. Phages can recognize bacterial receptors by specific structural
 188 proteins that can also have enzymatic activity able to degrade sugar polymers on the outer side of
 189 the cell wall of bacteria [18]. It has been shown that *Klebsiella pneumoniae* phages can produce
 190 polysaccharide depolymerases which are associated with the tail spike and even after phage
 191 inactivation the enzymes are still active and can form characteristic halo zones in spot agar plate
 192 assay [19]. In most cases these hydrolase enzymes are located on the phage tail and spikes, but they
 193 can also be produced as soluble proteins which are secreted to the environment [9].

194 In our previous work we have reported dual-function tail tubular proteins A (TTPA) containing
 195 hydrolytic activity towards bacterial polysaccharides [8,7]. Here, we show next Tail tubular protein
 196 from KP32 bacteriophage classified as form B (TTPB). It has been consider as structural protein,
 197 however, according to our results it is polysaccharide hydrolyzing enzyme. The screening analysis
 198 revealed that the protein is the most active towards *E. cloacae* strain. Its activity towards *K.*
 199 *pneumoniae* EPS has been also observed (data not shown). EPS produced by *K. pneumoniae* and by *E.*
 200 *cloacae* are closely resembling, hence both are TTPB's substrates [20].

201 The analysis of similarities in amino acid sequences using the BLAST program showed TTPB is
202 over 60% homologous to tail B protein (gp12) of T7 bacteriophage. Gp12 is classified as structural
203 protein, located in the bacteriophage tail core and it is important for phage adsorption to the
204 bacterial cell wall and host infection [21]. It has not been considered as an enzyme and its three-
205 dimensional structure has not been known so far. Thus it is not possible to predict the active site of
206 our TTPB comparing with TTPB from T7 bacteriophage.

207 The most important observation was the additive effect with kanamycin against bacterial biofilm
208 formation. The antibiotic could not reach the biofilmed bacterial cells and the situation was
209 completely different when the phage protein was present. To accurately characterize TTPB's
210 hydrolyzing activity it is necessary to conduct further biochemical studies using polysaccharides of
211 known structures. The study would provide extremely valuable information

212 In summary, in the presented study an attempt was made to demonstrate the utility of
213 bacteriophage tail tubular protein B to bacterial biofilm destruction. For the first time the hydrolytic
214 activity of the phage protein has been showed rendering it as dual-function protein. However, the
215 mechanism of action of this protein is still unclear and needs further investigation. Moreover, the
216 biochemical, physico-chemical and tertiary structure analyses of the protein should provide us
217 more information about the substrate binding site and catalytic domain occurrence.
218

219 **Acknowledgments:** The research was supported by National Science Centre, Poland no 2017/26/E/NZ1/00249
220 and Wroclaw Centre of Biotechnology, programme The Leading National Research Centre (KNOW) for years
221 2014-2018

222 **Author Contributions:** EB, KP, AP conceived and designed the experiments. EB, AP performed the
223 experiments. EB, AP, KP analyzed the data. EB,AP,KP,AG contributed to the writing of the manuscript.

224 **Conflicts of Interest:** The authors declare no conflict of interest

225

226 References

- 227 1. Babapour E., Haddadi A., Mirnejad R., Angaji S., Amirmozafari N. 'Biofilm Formation in
228 Clinical Isolates of Nosocomial *Acinetobacter Baumannii* and Its Relationship with Multidrug
229 Resistance'. *Asian Pacific Journal of Tropical Biomedicine*, 2016, 6, 528–33,
230 doi:10.1016/j.apjtb.2016.04.006
- 231 2. Nwodo U.U., Green E., Okoh A.I., Bacterial Exopolysaccharides: Functionality and
232 Prospects, *Int. J. Mol. Sci.* 2012, 13, 14002-14015; doi:10.3390/ijms131114002
- 233 3. Wyatt T., d'Alcalà M.R., Dissolved Organic Matter and planktonic engineering, CIESM
234 Workshop Monographs n°28, 2005
- 235 4. Jamal M., Tasneem U., Hussain T., Andleeb S., Bacterial Biofilm: Its Composition, Formation
236 and Role in Human Infections, *Research & Reviews: J. Microb. Biot.* 2015, 4, 1-14,
- 237 5. Harper, D.R., Parracho H. M. R. T, Walker J., Sharp R., Hughes G., Werthén M., Lehman S.,
238 Morales S., Bacteriophages and Biofilms, *Antibiotics (Basel)*. 2014; 3: 270–284, doi:
239 10.3390/antibiotics3030270
- 240 6. Pires D.P., Oliveira H., Melo L.D.R., Sillankorva S., Azeredo J., Bacteriophage-encoded
241 depolymerases: their diversity and biotechnological applications, *App. Microbiol. Biotechnol.*
242 2016, 100, 2141–2151, doi.org/10.1007/s00253-015-7247-0
- 243 7. Brzozowska E., Pyra A., Pawlik K., Janik M., Górska S., Urbańska N., Drulis-Kawa Z.,
244 Gamian A., Hydrolytic activity determination of Tail Tubular Protein A of *Klebsiella*
245 *pneumoniae* bacteriophages towards saccharide substrates, *Sc. Rep.*, 2017, 7:18048 |
246 DOI:10.1038/s41598-017-18096-1
- 247 8. Pyra A., Brzozowska E., Pawlik K., Gamian A., Dauter M., Dauter Z., Tail tubular protein A:
248 a dual-function tail protein of *Klebsiella pneumoniae* bacteriophage KP32, *Sc. Rep.*, 2017, 7,
249 2223, doi:10.1038/s41598-017-02451-3

- 250 9. Adams M.H., Park BH, An enzyme produced by a phage-host cell system. 11. The properties
251 of the polysaccharide depolymerase. 1956, *Viol.* 2: 719-736,
252 10. Adam M.H., Bacteriophage Interscience Publishers, Inc., New York 1959
253 11. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H. et al, Measurement of
254 protein using bicinchoninic acid. *Anal Biochem*, 1985, 150: 76–85
255 12. Laemmli, Cleavage of structural proteins during the assembly of the head of bacteriophage
256 T4. *Nature*, 1970, 227: 680–685
257 13. Nelson N., A photometric adaptation of the Somogyi method for the determination of
258 glucose. *J Biol Chem*. 1944, 153, 375-380
259 14. Kubler-Kielb J., Coxon B., Chneerson R., Chemical Structure, Conjugation, and Cross-
260 Reactivity of *Bacillus pumilus* Sh18 Cell Wall Polysaccharide, *J. Bacteriol.* 2004, 186: 6891-6901,
261 doi:10.1128/JB.186.20.6891-6901.2004
262 15. Rahman M., Kim S., Kim S.M., Seol S.Y., Kim J., Characterization of induced
263 *Staphylococcus aureus* bacteriophage SAP-26 and its anti-biofilm activity with rifampicin.
264 *Biofouling* 27, 2011, 1087-1093,doi: 10.1080/08927014.2011.631169.
265 16. Gilbert P., Maria-Litran T., McBain A.J., Rickard A.H.; Whyte F.W., The physiology and
266 collective recalcitrance of microbial biofilm communities; *Adv Microb Physiol* 2002, 46: 203-256
267 17. Donland R.M., Preventing biofilms of clinically relevant organisms using bacteriophage.
268 *Trends Microbiol*, 2009, 17: 66-72, doi: 10.1016/j.tim.2008.11.002.
269 18. Leiman P.G., Battisti A.J., Bowman V.D., Stummeyer K., Muhlenhoff M., et al, The
270 structures of bacteriophages K1E and K1-5 explain processive degradation of polysaccharide
271 capsules and evolution of new host specificities. *J Mol Biol*, 2007, 371: 836-849,
272 DOI:10.1016/j.jmb.2007.05.083
273 19. Kassa T., Chhibber S., Thermal treatment of the bacteriophage lysate of *Klebsiella*
274 *pneumoniae* B5055 as a step for the purification of capsular depolymerase enzyme. *J Virol*
275 *Methods* 2012, 179: 135-141,DOI:
276 [10.1016/j.jviromet.2011.10.011](https://doi.org/10.1016/j.jviromet.2011.10.011)
277 20. Raˆtto M., Verhoef R., Suihko M.L., Blanco A., Schols H.A., Voragen A.G.J., Wilting R.,
278 Siika-aho M., Buchert J. Colanic acid is an exopolysaccharide common to many enterobacteria
279 isolated from paper-machine slimes, *J Ind Microbiol Biotechnol* (2006) 33: 359–367, DOI
280 10.1007/s10295-005-0064-1
281 21. Kemp P., Garcia L.R, Molineux L.J., Changes in bacteriophage T7 virion structure at the
282 initiation of infection. *Virology*, 2005, 340: 307-317,